ArticlePloS one2026
Repeated dosing of myrrh, chamomile extract, and coffee charcoal reveals potential health-beneficial effects in patients with irritable bowel syndrome in the M-SHIME simulator.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo define the potential functional roles of a herbal preparation of myrrh, chamomile extract, and coffee charcoal in patients suffering from diarrhea dominant irritable bowel syndrome (IBS-D).
methodsThe study utilized the Mucosal Simulator of the Human Intestinal Microbial Environment (M-SHIME®) with proximal (PC) and distal colon (DC) compartments and fecal samples from four IBS-D donors. Eight-day (d) repeated dosing with the herbal product (6 tablets/day) was initiated compared to a negative control. Changes in microbial metabolism and community composition were assessed, and colonic ferments were evaluated for their effects on intestinal barrier permeability and cytokine production in a Caco-2/THP-1 co-culture model.
resultsProduct treatment significantly increased gas pressure versus negative control, indicating microbial fermentative activity. Product supplementation significantly increased proximal acetate (d3, d5), propionate (d3), and butyrate (d5, d8) levels (p < 0.05 for all), while no significant changes were observed distally. Ammonium levels were significantly elevated following product supplementation in PC (d3, d5, d8; p < 0.05) and DC (d8; p < 0.01), though remained within physiological range. Repeated dosing enriched members of Bifidobacteriaceae, Bacteroidota, Lachnospiraceae, and Butyricicoccus versus negative control. Treated colonic ferments had a protective effect on intestinal membrane integrity (DC; p < 0.001) and positive immunomodulatory effects (increased IL-10, PC and DC [both p < 0.0001], and IL-6, PC [p < 0.001] and DC [p < 0.01]) in Caco-2/THP-1 co-cultures.
conclusionsTreatment with a herbal preparation of myrrh, chamomile extract, and coffee charcoal showed a potential beneficial effect on the microbiota of patients with IBS-D in vitro, suggesting further exploration of its efficacy in IBS-D and other chronic gastrointestinal disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.